Table 2.
Biodistribution of rAAV9-CMV-hNAGLU in wild-type C57BL/6 mice
| 105 vg/μg DNA | |||
|---|---|---|---|
| Group 3 (2 × 1014 vg/kg) | Group 2 (1 × 1014 vg/kg) | ||
| Tissues | (6 weeks pi)a | (24 weeks pi)b | (24 weeks pi)c |
| Liver | 320.118 ± 327.119 | 20.218 ± 12.597 | 19.702 ± 8.237d |
| Kidney | 11.620 ± 7.122 | ||
| Spleen | 5.279 ± 2.433 | ||
| Heart | 11.789 ± 5.092 | ||
| Lung | 19.764 ± 9.751 | ||
| Pancreas | 6.626 ± 3.534 | ||
| Stomach | 7.325 ± 4.855 | ||
| Colon | 1.752 ± 1.344 | ||
| Lymph node | 14.498 ± 11.318 | ||
| Brain | 1.269 ± 1.266 | 0.394 ± 0.156 | 0.199 ± 0.132e |
| Spinal cord | 1.314 ± 1.139 | ||
| Ovary | 3.062 ± 2.002 | ||
| Testis | 1.891 ± 1.967 | ||
| Blood | 5.242 ± 5.149 | ||
Tissues were assayed by qPCR for rAAV9.CMV.hNAGLU vector genome. The vg values are means ± SD (n = 8–10/group).
a
qPCR assays were performed by CRL.
b
qPCR assays were performed by the corresponding author's lab.
c
No detectable vector genome in tissues from Group 1 saline control mice (<0.001 × 105 vg/μl DNA).
d
P > 0.05 vs. Group 3.
e
P = 0.05 vs. Group 3